

Howard A Burris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3114216/publications.pdf>

Version: 2024-02-01

80
papers

9,490
citations

218677

26
h-index

74163

75
g-index

82
all docs

82
docs citations

82
times ranked

14508
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	13.7	3,077
2	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	27.0	1,390
3	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2311-2319.	1.6	884
4	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. <i>Lancet Oncology, The</i> , 2017, 18, 42-51.	10.7	412
5	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	1.6	362
6	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology, The</i> , 2019, 20, 518-530.	10.7	362
7	Phosphatidylinositol 3-Kinase Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	1.6	298
8	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	27.0	220
9	A Phase II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4095-4106.	7.0	213
10	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	1.6	203
11	Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	7.1	187
12	Umbralisib, a novel PI3K γ and casein kinase-1 μ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. <i>Lancet Oncology, The</i> , 2018, 19, 486-496.	10.7	178
13	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology, The</i> , 2021, 22, 1290-1300.	10.7	178
14	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	1.6	173
15	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	1.6	149
16	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2028-2036.	1.6	111
17	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 278-284.	1.6	102
18	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1041-1048.	1.6	87

#	ARTICLE	IF	CITATIONS
19	Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. <i>Journal of Oncology Practice</i> , 2010, 6, 133-140.	2.5	77
20	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1133-1142.	10.7	76
21	A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. <i>European Journal of Cancer</i> , 2016, 56, 1-9.	2.8	76
22	Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 507-507.	1.6	55
23	Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2512-2512.	1.6	45
24	A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4501-4501.	1.6	43
25	Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	36
26	Safety, pharmacokinetics, and preliminary activity of the Î±-specific PI3K inhibitor BYL719: Results from the first-in-human study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2531-2531.	1.6	34
27	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 679-686.	6.4	31
28	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifestuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 364-372.	7.0	29
29	Successful Treatment With Dabrafenib (GSK2118436) in a Patient With Ganglioglioma. <i>Journal of Clinical Oncology</i> , 2014, 32, e98-e100.	1.6	27
30	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017, 35, 139-140.	1.6	22
31	TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 4154-4154.	1.4	20
32	Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2530-2530.	1.6	19
33	Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3044-3044.	1.6	18
34	A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2585-2585.	1.6	17
35	Targeted therapy for gastrointestinal (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase Ia basket study in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 653-653.	1.6	17
36	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16

#	ARTICLE	IF	CITATIONS
37	Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAB), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.. Journal of Clinical Oncology, 2013, 31, 3004-3004.	1.6	16
38	TGR-1202, a Novel Once Daily PI3KÎ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. Blood, 2014, 124, 1984-1984.	1.4	14
39	Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. Cancer Biology and Therapy, 2013, 14, 340-346.	3.4	13
40	Correcting the ASCO position on phase I clinical trials in cancer. Nature Reviews Clinical Oncology, 2020, 17, 125-125.	27.6	12
41	Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.. Journal of Clinical Oncology, 2013, 31, 2503-2503.	1.6	12
42	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.. Journal of Clinical Oncology, 2015, 33, 5513-5513.	1.6	12
43	First-in-human investigation of the oral first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.. Journal of Clinical Oncology, 2015, 33, TPS2615-TPS2615.	1.6	12
44	Extended <i>RAS</i> Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist, 2021, 26, e261-e269.	3.7	10
45	Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2506-2506.	1.6	10
46	Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). Lung Cancer, 2018, 118, 6-12.	2.0	9
47	Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study.. Journal of Clinical Oncology, 2015, 33, 297-297.	1.6	9
48	BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, TPS648-TPS648.	1.6	8
49	A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with nonâ~ small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).. Journal of Clinical Oncology, 2013, 31, 2507-2507.	1.6	8
50	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. Journal of Clinical Oncology, 2015, 33, 512-512.	1.6	8
51	Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.. Journal of Clinical Oncology, 2015, 33, 3520-3520.	1.6	7
52	A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Clinical Breast Cancer, 2020, 20, 89-97.	2.4	6
53	OncoAlert Round Table Discussions: The Global COVID-19 Experience. JCO Global Oncology, 2021, 7, 455-463.	1.8	6
54	A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.. Journal of Clinical Oncology, 2015, 33, TPS2624-TPS2624.	1.6	6

#	ARTICLE	IF	CITATIONS
55	cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).. Journal of Clinical Oncology, 2015, 33, 487-487.	1.6	6
56	A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer, 2022, 22, 269-278.	2.4	6
57	Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients. Blood, 2010, 116, 4015-4015.	1.4	5
58	MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.. Journal of Clinical Oncology, 2015, 33, TPS11111-TPS11111.	1.6	5
59	Developments in the Use of Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e99-e102.	3.8	4
60	First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2520-2520.	1.6	4
61	Clinical activity and safety profile of TGR-1202, a novel once daily PI3KÎ inhibitor, in patients with CLL and B-cell lymphoma.. Journal of Clinical Oncology, 2015, 33, 7069-7069.	1.6	4
62	Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 558-558.	1.6	4
63	Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. Lung Cancer, 2018, 117, 38-43.	2.0	3
64	Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 2461-2461.	1.4	3
65	BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR⁺, HER2⁻ advanced breast cancer.. Journal of Clinical Oncology, 2013, 31, TPS660-TPS660.	1.6	3
66	Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 523-523.	1.6	3
67	Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 3564-3564.	1.6	2
68	Developments in the Use of Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e99-e102.	3.8	2
69	Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute.. Journal of Clinical Oncology, 2013, 31, 5513-5513.	1.6	2
70	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	1.6	1
71	First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous <i>KRAS</i> wild type (WT) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8062-8062.	1.6	1
72	Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors.. Journal of Clinical Oncology, 2013, 31, e13045-e13045.	1.6	1

#	ARTICLE	IF	CITATIONS
73	A phase I/IB study of paclitaxel in combination with VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients (pts) with advanced ovarian cancer.. Journal of Clinical Oncology, 2013, 31, TPS2620-TPS2620.	1.6	1
74	Results of two phase I dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422.. Journal of Clinical Oncology, 2013, 31, 2617-2617.	1.6	1
75	A community-based program for personalized cancer care using next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 11102-11102.	1.6	1
76	KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8091-8091.	1.6	1
77	Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2544-2544.	1.6	0
78	Double-blind randomized phase II trial of carboplatin and pemetrexed with or without OGX-427 in patients with previously untreated stage IV non-squamous non-small-cell lung cancer (NSCLC): The Spruce Clinical Trial.. Journal of Clinical Oncology, 2013, 31, TPS8120-TPS8120.	1.6	0
79	Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.. Journal of Clinical Oncology, 2013, 31, 2093-2093.	1.6	0
80	Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma.. Journal of Clinical Oncology, 2015, 33, 2023-2023.	1.6	0